What prompted the cancellation of vascepa savings alerts?

What triggered the cancellation of Vascepa savings alerts?

The cancellation of Vascepa savings alerts was largely in response to a patent challenge from Amarin Pharma, the company behind Vascepa, an FDA-approved prescription fish oil medication used primarily to lower triglyceride levels. Vascepa's active pharmaceutical ingredient, icosapent ethyl, was initially covered under a patent held by GlaxoSmithKline (GSK) [1]. Amarin acquired the rights to icosapent ethyl and successfully challenged GSK's patent, which expired in 2020 [2].

However, the patent challenge and subsequent expiration didn't immediately trigger the cancellation of Vascepa savings alerts. The primary reason behind the cancellation was the expiration of the exclusive marketing rights granted to Amarin by the FDA for Vascepa. Initially, Amarin held exclusivity until December 2025, but the expiration allowed other companies to market generic versions of Vascepa [3].

As a result, Amarin announced its plan to discontinue the Vascepa Savings Offer program, which provided discounts for eligible patients, in response to the generic versions of the medication becoming available [4].

Why did Amarin discontinue the Vascepa Savings Offer program?

After the patent challenge and subsequent expiration, other companies began marketing generic versions of Vascepa. Amarin's pricing and market position were affected by the increased competition. As a response, Amarin discontinued the Vascepa Savings Offer program and other promotional discounts to adapt to the market changes and competition from generic medications.

How has Vascepa's market status changed since the patent challenge?

Vascepa is now subject to generic competition. Several pharmaceutical companies, such as Alvivia Pharmaceuticals and Kowa Pharmaceuticals America, have received FDA approval to market generic versions of the medication [5][6]. These new entrants into the market have altered Vascepa's pricing and availability, influencing Amarin's business strategies and the savings alerts provided to eligible patients.

Sources:
[1] - https://www.drugpatentwatch.com/patent/US8137945B2/
[2] - https://phx.corporate-ir.net/phoenix.zhtml?c=222997&p=irol-newsArticle&ID=2301455
[3] - https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-generic-vascepa
[4] - https://investors.amarin.com/news-release-detail/amrin-pharma-announces-launch-of-new-dosing-regimen-for-vascepa-and
[5] - https://www.drugpatentwatch.com/patent/US10439593B2/
[6] - https://www.drugpatentwatch.com/patent/US10811329B2/
[7] - https://www.drugpatentwatch.com/patent/US10811329B2/